Kotaro Yamashita1, Masayuki Watanabe2, Shinji Mine1, Takanori Kurogochi1, Akihiko Okamura1, Masaru Hayami1, Yu Imamura1. 1. Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. 2. Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. masayuki.watanabe@jfcr.or.jp.
Abstract
BACKGROUND: The recurrence patterns and therapeutic outcomes of patients with recurrent esophageal cancer after curative esophagectomy are not fully understood. METHODS: Data on recurrence patterns and sites of recurrence in patients with recurrent esophageal cancer after curative esophagectomy from 2005 to 2015 were retrospectively analyzed. Time to recurrence after curative esophagectomy and survival after recurrence were compared among groups stratified by recurrence pattern and site. Multivariate analysis was performed to identify clinicopathological parameters influencing survival after recurrence. RESULTS: Of the 290 patients identified, a single pattern of recurrence occurred in 224 patients (77.2%) and a multiple pattern of recurrence occurred in 66 patients (22.8%). The most frequent recurrence pattern was lymph node in 173 patients (59.7%), followed by distant organ in 133 patients (45.9%). Median time to recurrence and median survival after recurrence of all patients were 228 and 327 days, respectively. Among patients with lymph node or lung recurrence, there were 5-year survivors after recurrence who underwent multimodal therapy. Multivariate analysis revealed that longer disease-free interval [hazard ratio (HR) 0.70, 95% confidence interval (95% CI) 0.52-0.93], single pattern of recurrence (HR 0.54, 95% CI 0.39-0.74), and curative treatment for recurrence (HR 0.17, 95% CI 0.10-0.28) were significantly associated with favorable prognosis. CONCLUSIONS: Although the prognosis of recurrent esophageal cancer remains unfavorable, if multimodal treatment that includes local therapy was curative, prognosis could improve, especially in patients with lymph node or lung recurrence.
BACKGROUND: The recurrence patterns and therapeutic outcomes of patients with recurrent esophageal cancer after curative esophagectomy are not fully understood. METHODS: Data on recurrence patterns and sites of recurrence in patients with recurrent esophageal cancer after curative esophagectomy from 2005 to 2015 were retrospectively analyzed. Time to recurrence after curative esophagectomy and survival after recurrence were compared among groups stratified by recurrence pattern and site. Multivariate analysis was performed to identify clinicopathological parameters influencing survival after recurrence. RESULTS: Of the 290 patients identified, a single pattern of recurrence occurred in 224 patients (77.2%) and a multiple pattern of recurrence occurred in 66 patients (22.8%). The most frequent recurrence pattern was lymph node in 173 patients (59.7%), followed by distant organ in 133 patients (45.9%). Median time to recurrence and median survival after recurrence of all patients were 228 and 327 days, respectively. Among patients with lymph node or lung recurrence, there were 5-year survivors after recurrence who underwent multimodal therapy. Multivariate analysis revealed that longer disease-free interval [hazard ratio (HR) 0.70, 95% confidence interval (95% CI) 0.52-0.93], single pattern of recurrence (HR 0.54, 95% CI 0.39-0.74), and curative treatment for recurrence (HR 0.17, 95% CI 0.10-0.28) were significantly associated with favorable prognosis. CONCLUSIONS: Although the prognosis of recurrent esophageal cancer remains unfavorable, if multimodal treatment that includes local therapy was curative, prognosis could improve, especially in patients with lymph node or lung recurrence.
Authors: S Natsugoe; H Okumura; M Matsumoto; Y Uchikado; T Setoyama; Y Uenosono; S Ishigami; T Owaki; T Aikou Journal: Eur J Surg Oncol Date: 2006-03-29 Impact factor: 4.424
Authors: Feiran Lou; Camelia S Sima; Prasad S Adusumilli; Manjit S Bains; Inderpal S Sarkaria; Valerie W Rusch; Nabil P Rizk Journal: J Thorac Oncol Date: 2013-12 Impact factor: 15.609
Authors: M Yano; K Takachi; Y Doki; I Miyashiro; K Kishi; S Noura; H Eguchi; T Yamada; M Ohue; H Ohigashi; Y Sasaki; O Ishikawa; T Matsunaga; S Imaoka Journal: Dis Esophagus Date: 2006 Impact factor: 3.429
Authors: Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: Yichun Wang; Li Zhang; Dongmei Ye; Wanli Xia; Jun Jiang; Xiumei Wang; Mingxia Zhang; Fan Wang Journal: Oncol Lett Date: 2018-01-16 Impact factor: 2.967